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Classical Ehlers-Danlos syndrome (EDS) is characterized by skin hyperelasticity, joint hypermobility, increased
tendency to bruise, and abnormal scarring.Mutations in type V collagen, a regulator of type I collagen fibrillogenesis,
have been shown to underlie this type of EDS. However, to date, mutations have been found in only a limited
number of patients, which suggests genetic heterogeneity. In this article, we report two unrelated patients with
typical features of classical EDS, including excessive skin fragility, in whom we found an identical argininercysteine
substitution in type I collagen, localized at position 134 of the a1(I) collagen chain. The arginine residue is highly
conserved and localized in the X position of the Gly-X-Y triplet. As a consequence, intermolecular disulfide bridges
are formed, resulting in type I collagen aggregates, which are retained in the cells. Whereas substitutions of glycine
residues in type I collagen invariably result in osteogenesis imperfecta, substitutions of nonglycine residues in type
I collagen have not yet been associated with a human disease. In contrast, argininercysteine substitutions in type
II collagen have been identified in a variety of chondrodysplasias. Our findings show that mutations in other fibrillar
collagens can be causally involved in classical EDS and point to genetic heterogeneity of this disorder.
The Ehlers-Danlos syndrome (EDS) comprises a hetero-
geneous group of disorders affecting skin, ligaments and
joints, and blood vessels (Steinmann et al. 1993). The
most recent classification recognizes six subtypes, most
of which have been linked with genetic defects affecting
one of the fibrillar collagens (Beighton et al. 1998). Mu-
tations in type III collagen have been identified in the
vascular type of EDS (EDS IV [MIM 130050]) (Kui-
vaniemi et al. 1997). Structural mutations affecting the
procollagen I N-proteinase cleavage site were found in
the rare arthrochalasis variants of EDS (EDS VII A and
B [MIM 130060]) (Byers et al. 1997), whereas defects
of the enzymes lysylhydroxylase and procollagen I N-
proteinase are implicated in the recessive occuloscoliotic
(EDS VI [MIM 225400]) (Kuivaniemi et al. 1997) and
dermatosparaxis (EDS VII C [MIM 225410]) (Colige et
al. 1999) variants, respectively.
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Insights into the molecular basis of the common, clas-
sical types of EDS (EDS I and II [MIM 130000 andMIM
130010]) have only recently become available. These
EDS subtypes are characterizedmainly by hyperelasticity
of the skin, hyperlaxity of the joints, increased tendency
to bruise, and abnormal scarring. Transgenic mouse ex-
periments (Andrikopoulos et al. 1995) provided the first
evidence for the causal involvement of type V collagen
in this disorder. So far, however, 10 mutations in the
COL5A1 and COL5A2 genes have been reported in pa-
tients with classical EDS (Nicholls et al. 1996; Wenstrup
et al. 1996; De Paepe et al. 1997; Burrows et al. 1998;
Michalickova et al. 1998; Richards et al. 1998). This
raises the question of genetic heterogeneity in this EDS
variant. In this study, we found an identical argininer
cysteine substitution in the a1(I) collagen chain in two
unrelated patients with classical EDS. These findings
provide the first evidence for the causal involvement of
another fibrillar collagen in this disorder.
Patient 1, a 5-year-old girl and the only child of a
healthy nonconsanguineous couple, was born at 137 wk
of gestation, after premature rupture of membranes. She
had a history of easy bruising and scarring after minimal
trauma and presented a soft, velvety, and hyperexten-
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Figure 1 Ultrastructural findings in the skin of patient 2. A, On the transverse section (28,400#), the collagen fibrils show a distinct
variability in diameter; some fibrils are larger and irregular in outline (arrowhead). B, On the longitudinal section (28,400#), the deposition
of granulofilamentous material along the collagen fibrils is visible (arrowhead). In some foci, collagen fibrils have an unraveled and disorganized
aspect (arrow).
sible skin. In addition, she had atrophic paper scars on
the face, elbows, knees, and shins; ecchymoses on the
lower legs; and generalized joint hyperlaxity. Her facial
appearance, which included redundant skin folds on the
eyelids and very soft earlobes, was reminiscent of clas-
sical EDS. Her sclerae were white, and X-ray exami-
nation indicated that she had no signs of osteopo-
rosis.
Patient 2 was a 7-year-old boy, the only affected child
in a sibship of four children from healthy, nonconsan-
guineous parents. He was born at 137 wk of gestation
and showed hypotonia in the first months of life. An
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Figure 2 SDS-PAGE of radiolabeled, pepsin-digested collagens
from the medium (left) and the cell layer (right), produced by the
fibroblasts of patient 1. The pattern of the medium collagens is com-
parable to that of controls. In the cell layer, a population of dimeric
collagen a-chains is seen (arrow) that disappears after reduction. P =
patient 1; N = control samples.
operation was performed for strabismus.When clinically
examined at age 5 years, he had typical features of clas-
sical EDS, including a soft and doughy skin texture,
moderate skin hyperextensibility, and joint hyperlaxity.
In addition, he had a pronounced tendency for splitting
of the skin, easy bruising, and impaired wound healing.
He also presented an unusual tenderness of the skin and
soft tissues, evident when he was touched. He had a
pectus excavatum and flat feet. His sclerae were white,
and radiographic examination showed no signs of osteo-
porosis.
Ultrastructural studies performed on a skin biopsy
from patient 2 showed, on transverse section, a distinct
variability in the size of the collagen fibrils, with their
diameter in the range of 70–250 nm (fig. 1A). Some of
the fibrils were thicker and showed an irregular outline.
Longitudinal sections showed the presence of granulo-
filamentous material along the fibrils (fig. 1B). In some
foci, collagen fibrils had an unraveled aspect and ran in
a disorganized pattern. Mild dilatation of the rough en-
doplasmic reticulum was seen.
A dermal fibroblast culture was established from both
patients, and collagen and procollagen were studied by
SDS-PAGE after metabolic labeling with 14C-proline.
Analysis of the collagen and procollagen molecules se-
creted into the medium showed a normal pattern for
type I and type III collagen compared with control cell
lines. In patient 1, analysis of the cell-layer collagens
showed the presence of an additional band correspond-
ing to dimeric collagen a-chains (fig. 2), which migrated
higher up in the gel. In patient 2, a similar collagen
profile was seen, although the additional band repre-
senting the collagen dimers was of lesser intensity. The
dimers disappeared after reduction with b-mercapto-
ethanol, which suggests the presence of disulfide-
bounded collagen a-chains. Two-dimensional cyanogen
bromide peptide mapping showed that this additional
band was composed of a1(I) collagen chains (data not
shown). The thermal stability of the collagen dimers was
decreased by 1C compared with the normal a1(I) col-
lagen chains.
Mutation analysis of the COL1A1 cDNA sequence
was performed, and in half the clones a CrT transition
(nucleotide 934rexon 14) was identified, which resulted
in the substitution of arginine (CGC) for cysteine (TGC)
in position 134 of the procollagen a1(I) chain (fig. 3).
Analysis of the sequencing of the genomic DNA con-
firmed the mutation in both patients and showed it to
be absent in the parents. Because the a1(I)-R134C mu-
tation was not detectable by restriction digestion, ge-
nomic DNA from 50 control individuals was investi-
gated by SSCP analysis for the COL1A1–exon 14 area
and surrounding sequences, but no abnormal migration
shift was seen. The mutation was not found in 30 un-
related patients with classical EDS in whom a COL5A1
and COL5A2 mutation screening was negative. Muta-
tion analysis of the COL3A1, COL5A1, and COL5A2
cDNA was normal in both patients.
The mutation identified in both EDS patients was a
substitution of a basic arginine in the X position of the
Gly-X-Y triplet of the type I collagen a1 chain by an
uncharged polar cysteine, an amino acid residue, which
is not normally present in the triple helical domain of
type I collagen. The most common type of mutation in
type I collagen is the substitution of a glycine residue by
a bulkier amino acid, which has invariably been asso-
ciated with osteogenesis imperfecta (OI) (Kuivaniemi et
al. 1997). The presence of a glycine residue in every third
position of the collagen a-chain is essential for correct
folding of the helical domain of fibrillar collagen mol-
ecules. Glycinercysteine substitutions in the a1(I) col-
lagen chain are easily detected on biochemical analysis
by the presence of an additional band migrating in the
upper part of the gel, which consists of disulfide-
bounded a1(I) collagen chains.
In this study, however, the cysteine substitution in-
volves an arginine residue in the X position of the Gly-
X-Y triplet. As such, the cysteine residue projects on the
outside of the triple helix, enabling the formation of
intermolecular disulfide bridges between two adjacent
collagen molecules. This results in the formation of mo-
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Figure 3 Sequencing data from patient 1 representing the nor-
mal (upper panel) and the mutant (lower panel) COL1A1 allele. A
CrT transition changes the codon for arginine (CGC), in position 134
of the proa1(I) collagen chain, to the codon for cysteine (TGC).
lecular aggregates that cannot be secreted efficiently.
This may explain the dilatation of the endoplasmic re-
ticulum and the fact that the extra band representing
the dimeric type I collagen a-chains is detectable only
in the cell-layer samples and not in the medium samples
of the patient’s fibroblasts.
Mutant type I collagen molecules, which are not in-
volved in the intermolecular aggregates but harbor one
or two unbounded sulfhydryl groups, may cause local
intracellular perturbations and, once secreted, may in-
terfere with normal physiological interactions of the ex-
tracellular matrix components, disturbing normal col-
lagen fibril assembly. Glycinercysteine substitutions in
the a1(I) or a2(I) collagen chain, which cause OI, act
mainly at the level of molecular folding and fibril for-
mation, whereas the substitution of a nonglycine residue
by a cysteine most probably affects the molecular pack-
ing of the collagen fibrils and fibers through the presence
of unbounded sulfhydryl groups.
The fact that we identified this substitution in two
unrelated patients and found it to be absent in the un-
affected parents and 50 control individuals supports a
causal role for this mutation in classical EDS. Moreover,
the arginine residue involved is a highly conserved amino
acid in most of the fibrillar collagens and is therefore
probably important for normal fibrillar collagen
assembly.
So far, the substitution of a nonglycine residue in type
I collagen has not been associated with a clinical phe-
notype in humans. However, in type II collagen, the sub-
stitution of an arginine by a cysteine residue is associated
with a variety of chondrodysplasia phenotypes, includ-
ing spondyloepiphyseal dysplasia and Stickler-like syn-
dromes (Chan et al. 1993; Williams et al. 1993; Ballo
et al. 1998).
Mutations in the COL1A1 and COL1A2 gene that
abolish normal processing of the procollagen I N-pro-
teinase cleavage site have been shown to cause the rare
arthrochalasis variant of EDS. A certain degree of clin-
ical overlap between this form of EDS and OI exists,
since arthrochalasis patients commonly present osteo-
porosis, whereas patients with OI may show joint laxity
and some degree of skin hyperextensibility and abnor-
mal scarring. The children with EDS whom we studied,
however, lacked the major features of the arthrochalasis
type of EDS and showed no signs of osteoporosis.
To date, only mutations in the COL5A1 and COL5A2
genes have been identified in patients with classical EDS.
Type V collagen is a quantitatively minor component
among the fibrillar collagens, and it is coexpressed with
type I collagen in skin and tendon (Birk et al. 1990).
Type V collagen regulates the diameter of type I collagen
fibrils through its huge N-propeptide domain, which
protrudes from the surface of the type I collagen fibrils,
in which the type V molecules are buried (Birk et al.
1990). Since the a1(I)-R134C substitution results in the
same clinical phenotype as that associated with type V
mutations, it is possible that the mutation disturbs the
regulatory function of type V collagen in normal col-
lagen fibrillogenesis. Indeed, the ultrastructural abnor-
malities in the skin from patient 2 showed similar col-
lagen fibril abnormalities, as seen in the EDS patients in
whom a type V collagen mutation was identified.
The identification of a structural mutation in type I
collagen in two unrelated patients with classical EDS
provides formal proof of the genetic heterogeneity of
this EDS subtype. Moreover, recent studies, including
knock-out experiments, suggest that other connective-
tissue components, such as decorin (Danielson et al.
1997), thrombospondin-2 (Kyriakides et al. 1998), lum-
ican (Chakravarti et al. 1998), and tenascin-X (Burch et
al. 1997), may be causally involved in classical EDS.
In conclusion, our findings show that the substitution
of a nonglycine residue in type I collagen can cause clas-
sical EDS. Further study of the contribution of type I
collagen defects in this EDS subtype is warranted.
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